

IMPROVED IMPACT ON CLINICAL OUTCOMES & REDUCED COSTS: Switching amino acid-based formulas



**Amino acid-based formulas (AAF)
with medium chain triglycerides
are important for managing:**



Cow's milk protein
allergy (CMPA)



Multiple
food allergies



Eosinophilic
GI disorders,
e.g. EoE



Food protein induced
enterocolitis
syndrome (FPIES)



Fat malabsorption &
malabsorptive conditions, e.g.
short bowel syndrome (SBS)

STUDY FOCUS

OBJECTIVE: Evaluate the clinical and economic impact of switching children <18 years from one AAF (EleCare®) to another (Alfamino®) during the 2022 U.S. formula shortage in post-acute care settings.

DESIGN: Retrospective analysis pre- (6 months prior) and post-switch (1,3,6 months after) of tolerance, gastrointestinal (GI) and allergy symptoms, healthcare resource utilization (HCRU), and associated costs.



TOTAL PARTICIPANTS
402
children

PARTICIPANT AGE
1–3 years
43% of
participants

STUDY TIMEFRAME
2022
formula
shortage

Formula Studied	Alfamino Infant	Alfamino Junior	Elecare™ Infant	Elecare™ Junior
% MCT** of total fat	43%	65%	33%	33%

RESULTS



DISCUSSION AND CONCLUSION

Alfamino had a greater % of MCT as total fat, and it is possible that this may have attributed to improved GI symptoms as MCTs help with fat absorption.

Children in post-acute care settings who transitioned to an alternate amino acid-based formula (Alfamino) experienced significantly improved:

✓ CLINICAL OUTCOMES
58% less reports of
GI intolerance symptoms
after switching[§]

✓ HEALTHCARE VISITS
70% fewer mean
healthcare visits[†]

✓ ASSOCIATED COSTS
86% reduction in
total associated costs[#]

SCAN to see the author
present the study details



- ** MCT = Medium Chain Triglycerides
- † GI intolerance symptoms included abdominal distension, constipation, diarrhea, flatulence and nausea and vomiting
- ‡ Healthcare visits included outpatient, inpatient, emergency department, urgent care, telemedicine, and other
- § 148 patients pre-switch vs. 61 patients at 1 month post-switch
- ¶ A mean of 76 visits pre-switch vs. a mean of 23 visits at 1 month post-switch
- # \$670K total cost vs. \$93K cost at 1 month post-switch

The complete publication may be accessed online: Improved Impact on Clinical Outcomes and Reduced Cost of Care Associated With Switching Hypoallergenic Amino Acid-Based Formulas.

REFERENCE: Thakkar K, Cekola P, Boccella J, Desai A, Kumar P, Mondal S., Vijayakadam Y, Samal C., Klosterbuer A. *Sage Open Pediatrics* 2025;12: 1–11.